Tenaya Therapeutics Says Expects No Impact On TN-201 Timelines From Hold; Says Working To Resolve Clinical Hold And Resume Dosing
Benzinga News 07/11 21:27
HC Wainwright & Co. Reiterates Buy on Humacyte, Maintains $15 Price Target
Humacyte, Inc. - Common Stock +1.53%
Humacyte, Inc. - Common Stock HUMA | 0.00 |
HC Wainwright & Co. analyst Vernon Bernardino reiterates Humacyte (NASDAQ:
HUMA) with a Buy and maintains $15 price target.
Recommend
Is BioCryst’s Surging ORLADEYO Sales and Astria Deal Reshaping the Investment Case for BCRX?
Simply Wall St 08/11 03:35Amgen (AMGN): Assessing Valuation After Strong Q3 Growth and Raised 2025 Guidance
Simply Wall St 08/11 06:37Why Denali Therapeutics (DNLI) Is Down 7.7% After Widening Losses and Key Leadership Changes
Simply Wall St 08/11 14:18Can AbCellera (ABCL) Balance Rising Revenues and Widening Losses to Fund Its Innovation Pipeline?
Simply Wall St 08/11 20:33Natera (NTRA): Reassessing Valuation After Raised 2025 Guidance and Strong Quarterly Results
Simply Wall St 09/11 05:19Vericel (VCEL): Evaluating Valuation After MACI Revenue Surge and New Growth Initiatives
Simply Wall St 09/11 12:29Catalyst Pharmaceuticals (CPRX): Valuation Insights After Strong Q3 Results and New Share Buyback Program
Simply Wall St 09/11 13:29
